JOHNSON & JOHNSON COVID VACCINE FLAGGED FOR RARE BLOOD CLOTS IN THE U.S.

Apr 13, 2021

By Jane Brown

Share on

There is a recommendation in the U.S. for a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of clotting.

In a joint statement, the U.S. Centers for Disease Control and the Food and Drug Administration say they are recommending a suspension of the J & J vaccine to investigate reports of potentially dangerous blood clots in six women in the days after vaccination.

The clots were observed along with reduced platelet counts making the usual treatment for blood clots, the blood thinner heparin, potentially “dangerous.”

It is important to note, more than 6.8-million doses of the Johnson & Johnson vaccine have been administered in the U.S., but none have been received or given in Canada to date, although the J and J vaccine is approved for use in Canada.

The is the second time a COVID vaccine has been flagged for a possible link to rare blood clots. The other is the AstraZeneca, which has been cleared for use in people 55 and older here in Canada. The AstraZeneca vaccine has not yet received authorization in the U.S.

Join Our Fan Club
Coverage Area
Downtown Toronto
96.7FM
Toronto HD
96.3 HD-2
Kingston to Windsor, Parry Sound to Pittsburgh
AM740
ZoomerRadio Logo

Recently Played: